AT9283
Published: Nov 10, 2010 5:56 pm
| Brand Name: | |
| Generic Name: | |
| Code Name: | AT9283 |
| Company: | Astex |
| FDA Clinical Phase: | 2 |
Description:
AT9283 is a kinase inhibitor that prevents cell division, thereby stopping the growth of cancer cells. Several Phase 1 clinical trials have shown that AT9283 is safe in patients with blood and solid-tumor cancers, and pre-clinical studies have indicated that AT9283, alone or in combination with other myeloma treatments, is effective in multiple myeloma cells.
Clinical Trials:
For a list of clinical trials studying AT9283 for the treatment of multiple myeloma, see ClinicalTrials.gov.
Website for AT9283: http://www.astex-therapeutics.com/products/pipeline.php
Related Articles:
- Latest Myeloma Research To Be Presented At The American Society Of Clinical Oncology Annual Meeting (ASCO 2018)
- Eyelid-Related Complications Of Velcade Therapy: New Insights And Recommendations
- Two Darzalex Clinical Trials Halted; Little Impact Expected On Drug’s Use In Multiple Myeloma
- Dr. Christoph Driessen On Nelfinavir In The Treatment Of Multiple Myeloma
- Once-Weekly High-Dose Kyprolis Yields Deeper Responses And Longer Remissions Than Twice-Weekly Kyprolis (ASCO & EHA 2018)